Retrospective, post-marketing safety surveillance study of Xarelto in patients with venous thromboembolisms

Trial Profile

Retrospective, post-marketing safety surveillance study of Xarelto in patients with venous thromboembolisms

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Dec 2016 New trial record
    • 06 Dec 2016 Results (n=9638) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Dec 2016 Results published in a Janssen Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top